Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2024 | Advice for physicians treating MCL: sequencing and selection of BTKis

Krish Patel • 6 Sep 2024
SOHO 2024
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma BTK degraders BTK inhibitors Pirtobrutinib

Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, provides advice for physicians treating patients with mantle cell lymphoma (MCL) with BTK inhibitors (BTKis), highlighting some considerations when switching between agents due to progression or intolerance. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Krish Patel

Exploring dual-antigen targeting in LBCL: insights into axi-cel plus rituximab data from ZUMA-14
0:59
Exploring dual-antigen targeting in LBCL: insights into axi-cel plus rituximab data from ZUMA-14
Krish Patel • 11 Sep 2026
Evaluating pirtobrutinib in patients with R/R MZL exposed to BTKis: BRUIN cohort data
1:02
Evaluating pirtobrutinib in patients with R/R MZL exposed to BTKis: BRUIN cohort data
Krish Patel • 11 Sep 2026
Deciding between bispecifics and CAR-T in R/R follicular lymphoma
1:28
Deciding between bispecifics and CAR-T in R/R follicular lymphoma
Krish Patel • 11 Sep 2026
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
25:30
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
Akil Merchant et al. • 26 Apr 2026

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals